Determination of Regulatory Review Period for Purposes of Patent Extension; Maxalt

Summary

The US Food and Drug Administration (FDA) has determined the regulatory review period for the patent extension of Maxalt, a human drug product, and is publishing this notice as required by law. The FDA made this determination due to a submission to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of the patent.